MAPT and Alzheimer disease: Therefore, before a reliable early AD biomarker that informs the time of early treatment, apomorphine and raloxifene seem to be excellent candidates for clinical trials on TBI patients to stop the progression of damages caused by abnormally phosphorylated tau following the impact.